HALOZYME THERAPEUTICS, INC. (HALO) Operating Margin
- Operating margin · 12 months: Value 35.90%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 35.90% | Operating income / revenue. Period ending 2026-06-30. $597.20M ÷ $1.66B × 100 ≈ 35.90% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 597.20M USD | Operating Income (Loss) |
| Revenue | 1.66B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 292.42M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 238.00M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $597.20M | $1.66B | $292.42M | (m) | $238.00M | 35.90% |
| 2026-03-31 | $511.99M | $1.51B | $259.61M | (m) | $222.61M | 33.94% |
| 2025-12-31 | $469.01M | $1.40B | $228.77M | (m) | $207.09M | 33.58% |
| 2025-09-30 | $737.40M | $1.24B | $192.06M | $70.03M | $172.31M | 59.33% |
| 2025-06-30 | $682.67M | $1.18B | $186.24M | $71.24M | $167.47M | 57.92% |
| 2025-03-31 | $597.47M | $1.08B | $179.49M | $74.74M | $161.56M | 55.10% |
| 2024-12-31 | $551.48M | $1.02B | $159.42M | $79.05M | $154.34M | 54.32% |
| 2024-09-30 | $477.01M | $947.36M | $169.66M | $79.94M | $149.69M | 50.35% |
| 2024-06-30 | $402.09M | $873.30M | $175.06M | $78.81M | $143.72M | 46.04% |
| 2024-03-31 | $379.31M | $862.99M | $185.52M | $77.50M | $146.96M | 43.95% |
| 2023-12-31 | $337.57M | $829.25M | $192.36M | $76.36M | $149.18M | 40.71% |
| 2023-09-30 | $311.05M | $780.71M | $182.18M | $77.59M | $149.32M | 39.84% |
| 2023-06-30 | $306.06M | $773.65M | $174.68M | $76.98M | $148.52M | 39.56% |
| 2023-03-31 | $245.66M | $704.98M | $158.55M | $72.73M | $167.05M | 34.85% |
| 2022-12-31 | $267.53M | $660.12M | $139.30M | $66.61M | $143.53M | 40.53% |
| 2022-09-30 | $249.56M | $580.62M | $118.77M | $54.15M | $119.55M | 42.98% |
| 2022-06-30 | $241.85M | $487.48M | $90.04M | $45.93M | $98.25M | 49.61% |
| 2022-03-31 | $300.84M | $471.57M | $79.12M | $38.52M | $53.10M | 63.80% |
| 2021-12-31 | $275.90M | $443.31M | $81.41M | $35.67M | $50.32M | 62.24% |
| 2021-09-30 | $296.99M | $463.01M | $86.10M | $32.94M | $46.98M | 64.14% |
| 2021-06-30 | $261.70M | $412.50M | $73.08M | $32.20M | $45.51M | 63.44% |
| 2021-03-31 | $198.21M | $331.26M | $55.80M | $33.09M | $44.16M | 59.84% |
| 2020-12-31 | $144.25M | $267.59M | $43.37M | $34.24M | $45.74M | 53.91% |
| 2020-09-30 | $34.57M | $199.56M | $33.78M | $71.97M | $59.24M | 17.32% |
| 2020-06-30 | $-30.27M | $180.47M | $50.55M | $94.67M | $65.52M | -16.77% |
| 2020-03-31 | $-73.80M | $164.40M | $46.68M | $119.63M | $71.88M | -44.89% |
| 2019-12-31 | $-67.61M | $195.99M | $45.55M | $140.80M | $77.25M | -34.50% |
| 2019-09-30 | $-35.62M | $202.56M | (m) | $132.34M | $71.35M | -17.58% |
| 2019-06-30 | $-36.56M | $181.88M | (m) | $137.43M | $68.24M | -20.10% |
| 2019-03-31 | $-42.65M | $177.94M | (m) | $143.60M | $65.25M | -23.97% |
| 2018-12-31 | $-69.33M | $151.86M | (m) | $150.25M | $60.80M | -45.65% |
| 2018-09-30 | $56.67M | $281.19M | (m) | $154.98M | $57.54M | 20.15% |
| 2018-06-30 | $90.22M | $319.37M | (m) | $153.43M | $56.01M | 28.25% |
| 2018-03-31 | $84.82M | $317.92M | (m) | $151.68M | $54.76M | 26.68% |
| 2017-12-31 | $81.00M | $316.61M | (m) | $150.64M | $53.82M | 25.58% |
| 2017-09-30 | $-67.50M | $166.05M | (m) | $150.62M | $51.27M | -40.65% |
| 2017-06-30 | $-98.32M | $134.17M | (m) | $150.49M | $49.54M | -73.28% |
| 2017-03-31 | $-94.57M | $133.76M | (m) | $147.68M | $47.66M | -70.70% |
| 2016-12-31 | $-83.21M | $146.69M | (m) | $150.84M | $45.85M | -56.72% |
| 2016-09-30 | $-55.17M | $159.91M | (m) | $137.24M | $44.22M | -34.50% |
| 2016-06-30 | $-55.66M | $148.84M | (m) | $130.99M | $42.84M | -37.40% |
| 2016-03-31 | $-29.71M | $158.89M | (m) | $116.65M | $41.44M | -18.70% |
| 2015-12-31 | $-27.45M | $135.06M | (m) | $93.24M | $40.03M | -20.33% |
| 2015-09-30 | $-36.77M | $113.21M | (m) | $85.22M | $37.79M | -32.48% |
| 2015-06-30 | $-32.56M | $107.03M | (m) | $77.51M | $36.15M | -30.42% |
| 2015-03-31 | $-51.73M | $82.03M | (m) | $74.97M | $35.09M | -63.06% |
| 2014-12-31 | $-63.04M | $75.33M | (m) | $79.70M | $35.94M | -83.68% |
| 2014-09-30 | $-80.51M | $57.46M | (m) | $80.89M | $36.95M | -140.12% |
| 2014-06-30 | $-79.98M | $58.86M | (m) | $86.68M | $36.49M | -135.87% |
| 2014-03-31 | $-87.16M | $54.93M | (m) | $96.02M | $35.04M | -158.67% |
| 2013-12-31 | $-80.43M | $54.80M | (m) | $96.64M | $32.35M | -146.78% |
| 2013-09-30 | $-63.52M | $64.09M | (m) | $94.28M | $29.97M | -99.10% |
| 2013-06-30 | $-65.05M | $53.42M | (m) | $88.10M | $27.47M | -121.79% |
| 2013-03-31 | $-56.98M | $46.72M | (m) | $76.19M | $25.75M | -121.97% |
| 2012-12-31 | $-53.63M | $42.33M | (m) | $70.04M | $24.81M | -126.70% |
| 2012-09-30 | $-67.65M | $22.94M | (m) | $66.39M | $23.70M | -294.85% |
| 2012-06-30 | $-42.46M | $40.55M | (m) | $60.40M | $22.33M | -104.72% |
| 2012-03-31 | $-25.32M | $55.98M | (m) | $59.67M | $21.32M | -45.23% |
| 2011-12-31 | $-19.84M | $56.09M | (m) | $57.56M | $18.10M | -35.37% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-54.26M | $13.62M | (m) | $51.77M | $15.12M | -398.25% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-58.46M | $13.67M | (m) | $56.61M | $15.20M | -427.60% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |